The Trulicity pen. Once-weekly GLP-1 from Eli Lilly in focus

Trulicity 1.5 mg solution for injection in prefilled pen sits cold and smooth in the palm before use, its green push-button waiting for a single click. The disposable pen delivers a once-weekly dose for adults with type 2 diabetes, no vial or syringe needed.

Once-weekly GLP-1 therapy

Trulicity is Eli Lilly’s brand name for dulaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist indicated for adults with type 2 diabetes to improve glycaemic control, and to reduce the risk of major cardiovascular events in those with established cardiovascular disease. Official prescribing information from Eli Lilly details the indications and dosing.

The Trulicity 1.5 mg strength is one of several dose options in the range, with others including 0.75 mg, 3 mg and 4.5 mg pens for once-weekly subcutaneous injection. The manufacturer’s dosing page lists the full pen portfolio and strengths. Adults typically inject Trulicity under the skin in the abdomen, thigh, or upper arm, rotating sites week by week.

Pen design and patient handling

The Trulicity pen is a single-use, prefilled device with an integrated needle that remains hidden before and after injection, reducing visual anxiety for needle-sensitive patients. Lilly’s patient instructions explain the one-button injection sequence. The user simply unlocks, places the base on the skin, then presses the green button until a second click confirms completion.

The plastic casing feels slightly textured rather than slippery, giving some grip even in a humid bathroom or clinic setting. A subtle vibration and a soft mechanical click signal that the dose is being delivered. For patients, this tactile feedback helps distinguish a successful injection from a misfire, without requiring them to see the needle.

Clinical profile and safety signals

Chief executive David A. Ricks frequently highlights Lilly’s incretin portfolio, including Trulicity, as a mainstay of the company’s metabolic business in earnings calls. A Reuters report summarises his comments on GLP-1 growth. Clinically, dulaglutide improves blood glucose by enhancing glucose-dependent insulin secretion and slowing gastric emptying, and many patients also experience weight reduction as an additional outcome.

Regulatory agencies emphasise that Trulicity is not approved specifically for weight loss; its marketing authorisation focuses on diabetes and cardiovascular risk reduction. The European Medicines Agency’s assessment report sets out indications and contraindications. Gastrointestinal adverse reactions such as nausea, diarrhoea and vomiting are the most common side effects seen in trials, particularly in early weeks before patients adapt.

Positioning next to Mounjaro

While social media feeds are flooded with before-and-after snapshots labelled “Mounjaro”, Trulicity remains a workhorse diabetes product prescribed at scale. In many health systems, dulaglutide has been on formularies for years, making it familiar to endocrinologists and primary care physicians. This embedded base creates a steady prescription flow, even as newer dual-agonist molecules gain momentum.

Lilly increasingly positions Trulicity as a tried-and-tested GLP-1 option for patients who may not yet be candidates for newer agents, or whose insurance coverage favours established therapies. In practice, clinicians often transition patients stepwise, from oral agents such as metformin to injectable GLP-1 therapy like Trulicity, and only later consider newer molecules when clinically justified.

Manufacturing, supply and availability

Dulaglutide pens are manufactured and filled under cold-chain and sterile conditions at Lilly’s facilities, with global distribution spanning the United States, Europe, and multiple other markets. In Europe, Trulicity has been authorised since 2014, with country-by-country reimbursement decisions shaping access and pricing. NICE guidance in the UK illustrates reimbursement criteria and clinical positioning.

Recent years have seen intermittent supply pressure across the GLP-1 class, driven largely by soaring demand for weight-management use in parallel brands. Trulicity has felt these pressures too, with some wholesalers reporting temporary constraints. Lilly and peers are investing heavily in capacity expansions to stabilise availability for diabetes patients who rely on these weekly injections.

Medication handling and user training

From a user’s perspective, Trulicity arrives in refrigerated packaging and must be stored in the fridge until use, then brought to room temperature for a more comfortable injection. The pen’s rounded edges avoid sharp corners on the skin, and the integrated needle stays covered, reducing the risk of accidental sticks when handling used devices.

Nurses often demonstrate the injection routine with a trainer pen during the first consultation, letting patients feel the button and hear the click without delivering drug. That hands-on rehearsal can ease the first home injection. Many patients report the sensation as a short, mild pressure rather than a sharp sting, especially when the pen is held firmly against the skin.

Market segment and stock context

In the broader GLP-1 segment, Trulicity occupies the well-established diabetes corner, balancing newer obesity-focused launches in Lilly’s portfolio. For health insurers and national health systems, its predictability and long-term data are valuable in treatment algorithms. The Trulicity line contributes meaningful recurring revenue as prescriptions roll weekly, behind the spotlight currently shining on Mounjaro and Zepbound.

On Xetra, Eli Lilly and Co. stock trades via euro-denominated instruments, with investors closely tracking volumes and pricing in the GLP-1 and incretin segment alongside broader oncology and immunology franchises.